Direct Cardiac Epigenetic Reprogramming through Codelivery of 5′Azacytidine and miR-133a Nanoformulation

Direct reprogramming of cardiac fibroblasts to induced cardiomyocytes (iCMs) is a promising approach to cardiac regeneration. However, the low yield of reprogrammed cells and the underlying epigenetic barriers limit its potential. Epigenetic control of gene regulation is a primary factor in maintain...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Molecular Sciences Vol. 23; no. 23; p. 15179
Main Authors: Muniyandi, Priyadharshni, Palaninathan, Vivekanandan, Hanajiri, Tatsuro, Maekawa, Toru
Format: Journal Article
Language:English
Published: Basel MDPI AG 01.12.2022
MDPI
Subjects:
Azacitidine
Cardiomyocytes
Cell differentiation
Cellular Reprogramming
DNA Methylation
Efficiency
Epigenetic inheritance
Epigenetics
Fibroblasts
Gene expression
Gene Expression Regulation
Heart
Humans
Methylation
MicroRNAs
Morphology
Myocytes, Cardiac
Nanoparticles
nanovectors; non-viral gene therapy; epigenetic reprogramming; direct reprogramming; 5′Azacytidine; MicroRNAs
Polymers
Polyvinyl alcohol
Singh, Vishwanath Pratap
Stem cells
Japan
ISSN:1422-0067, 1661-6596, 1422-0067
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Direct reprogramming of cardiac fibroblasts to induced cardiomyocytes (iCMs) is a promising approach to cardiac regeneration. However, the low yield of reprogrammed cells and the underlying epigenetic barriers limit its potential. Epigenetic control of gene regulation is a primary factor in maintaining cellular identities. For instance, DNA methylation controls cell differentiation in adults, establishing that epigenetic factors are crucial for sustaining altered gene expression patterns with subsequent rounds of cell division. This study attempts to demonstrate that 5′AZA and miR-133a encapsulated in PLGA-PEI nanocarriers induce direct epigenetic reprogramming of cardiac fibroblasts to cardiomyocyte-like cells. The results present a cardiomyocyte-like phenotype following seven days of the co-delivery of 5′AZA and miR-133a nanoformulation into human cardiac fibroblasts. Further evaluation of the global DNA methylation showed a decreased global 5-methylcytosine (5-medCyd) levels in the 5′AZA and 5′AZA/miR-133a treatment group compared to the untreated group and cells with void nanocarriers. These results suggest that the co-delivery of 5′AZA and miR-133a nanoformulation can induce the direct reprogramming of cardiac fibroblasts to cardiomyocyte-like cells in-vitro, in addition to demonstrating the influence of miR-133a and 5′AZA as epigenetic regulators in dictating cell fate.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms232315179